Filter Results:
(610)
Show Results For
- All HBS Web
(610)
- People (4)
- News (110)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
Show Results For
- All HBS Web
(610)
- People (4)
- News (110)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
- Web
Health Care - Faculty & Research
transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda,... View Details
- March 2015 (Revised September 2016)
- Case
Terrapin Laboratory
By: Richard G. Hamermesh and Joseph B. Fuller
Describes the formation and rapid growth of a drug testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. The associated teaching materials provide students the opportunity... View Details
Keywords: Business Growth; Entrepreneurial Management; Entrepreneurship; Growth Strategy; Market Entry; Venture Capital; Growth Management; Expansion; Financing and Loans; Health Care and Treatment; Health Testing and Trials; Business Startups; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., and Joseph B. Fuller. "Terrapin Laboratory." Harvard Business School Case 315-098, March 2015. (Revised September 2016.)
- 12 Apr 2010
- Research & Ideas
One Report: Better Strategy through Integrated Reporting
electronics company Philips; the Danish pharmaceutical company Novo Nordisk; the Brazilian cosmetics company Natura; and the U.S.-based... View Details
Keywords: by Martha Lagace
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
markets have tightened, it's the companies with highly differentiated products that will be able to not only weather this storm, but come out the other side" in a strong position, says Harvard Business School Professor of Management... View Details
- January 2005 (Revised March 2006)
- Case
Molecular Insight Pharmaceuticals, Inc.
By: Richard G. Hamermesh and Edwin W. Parkinson III
Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing.... View Details
Keywords: Intellectual Property; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, January 2005. (Revised March 2006.)
- 15 Jul 2013
- Research & Ideas
Five Imperatives for Improving Health Care
necessarily contribute to overall value," Huckman says. "Think about a company that runs very profitable hospitals. Are they profitable because they've figured out how to offer high quality care at low cost? Or are they... View Details
- 13 Jul 2023
- News
The Network Effect
between the two companies. In March 2021, Model was a part of the Agios team that finalized the sale of the biotech’s oncology portfolio to international pharmaceutical company Servier. For Agios, the sale... View Details
- February 2010
- Background Note
Millipore Background Note
By: Elie Ofek and Natalie Kindred
This note provides background on Millipore Corporation, a global provider of products and services used primarily in the discovery, development and production of therapeutic drugs. With a track record of quickly adapting to the evolving needs of its customers,... View Details
Keywords: Organizational Change and Adaptation; Customer Focus and Relationships; Pharmaceutical Industry; Pharmaceutical Industry
Ofek, Elie, and Natalie Kindred. "Millipore Background Note." Harvard Business School Background Note 510-059, February 2010.
- April 2017
- Supplement
Imprimis (D)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A, B, & C). It describes Imprimis’s 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750 per pill. Imprimis also... View Details
Keywords: Decision Choices and Conditions; Growth and Development Strategy; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (D)." Harvard Business School Supplement 717-498, April 2017.
- June 2016
- Teaching Plan
Terrapin Laboratory
By: Joseph B. Fuller and Andrew Otazo
This teaching plan accompanies the case "Terrapin Laboratory," HBS No. 315-098. That case describes the formation and rapid growth of a drug testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug... View Details
- 01 Jun 2024
- News
Quantum Leap
pharmaceutical and chemical industries have taken note: The venture capital arm of the pharma giant Merck, for instance, invested $5 million in SEEQC’s Series A round, where it was joined by the South Korean chemical View Details
- 01 Sep 2023
- News
Research Brief: Making Way for Moonshots
Josh Krieger (Courtesy subject) Josh Krieger (Courtesy subject) Many innovations in modern medicine have come about due to cutting-edge drugs—advances that required both a scientific leap and a willingness to take risks. And while most pharmaceutical companies would... View Details
Keywords: Jen McFarland Flint
- 21 Sep 2022
- Research & Ideas
You Don’t Have to Quit Your Job to Find More Meaning in Life
though one is leading a meaningful life is a bellwether for broader emotional wellbeing, with those who feel they are leading meaningful lives displaying superior mental and physical health. Making work meaningful can also be key for View Details
Keywords: by Shalene Gupta
- January 2017
- Supplement
Terrapin Laboratory: Exercise
By: Joseph B. Fuller and Christopher Payton
In this exercise, we examine the capital requirements of Terrapin Laboratory as they contemplate entering into a new market segment. The company is faced with two potential financing options which have different effects on the ownership structure of the company.... View Details
- December 2005 (Revised October 2006)
- Case
Pharmacy Service Improvement at CVS (A)
CVS's retail pharmacy operations are functioning poorly and dissatisfying customers. Many customers are defecting as a result. A pharmacy service improvement team has documented the current prescription fulfillment process, its exception rates, and the problems... View Details
Keywords: Information Technology; Performance Improvement; Business Processes; Pharmaceutical Industry; Pharmaceutical Industry; United States
McAfee, Andrew P. "Pharmacy Service Improvement at CVS (A)." Harvard Business School Case 606-015, December 2005. (Revised October 2006.)
- January 2009 (Revised July 2009)
- Case
Targanta Therapeutics: Hitting a Moving Target
By: Arthur A. Daemmrich
This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Decision Choices and Conditions; Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Business and Government Relations; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Daemmrich, Arthur A. "Targanta Therapeutics: Hitting a Moving Target." Harvard Business School Case 709-002, January 2009. (Revised July 2009.)
- August 2017 (Revised July 2018)
- Case
MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work
By: Elie Ofek and Amanda Dai
In June 2014, MannKind Corporation announced that after years of development and billions of dollars in expenses, the FDA had finally approved its drug, Afrezza. MannKind would thus be the only company with an inhalable insulin on the market. As an alternative to... View Details
Keywords: Health Care and Treatment; Product Launch; Product Positioning; Marketing Strategy; Adoption; Pharmaceutical Industry
Ofek, Elie, and Amanda Dai. "MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work." Harvard Business School Case 518-031, August 2017. (Revised July 2018.)
- January 2023
- Teaching Note
The Opioid Settlement and Executive Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged... View Details
Keywords: Opioids; Shareholder Activism; Investment Activism; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Executive Compensation; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
- 22 Feb 2024
- News
Combat-Tested Cancer Coaching
Subscribe on iTunes Subscribe on Spotify More Skydeck episodes Hi, this is Dan Morrell, host of Skydeck. When Kathy Giusti (MBA 1985) was diagnosed with multiple myeloma in 1996, she was overwhelmed. It was the pre-Internet era, with limited available information, but... View Details
- 23 May 2000
- Research & Ideas
Minding the Muse: The Impact of Downsizing on Corporate Creativity
pharmaceutical firms that rely on creativity," she says. "Today's fast-changing global markets place increased pressure on companies of every kind to continuously create new products, services, and... View Details
Keywords: by Peter K. Jacobs